Geron phase 3 imetelstat. Please find resources and i...
Geron phase 3 imetelstat. Please find resources and information about their products and services through the links on this page. These results support continued evaluation of imetelstat sodium 9. The management of Grade 3 and Grade 4 adverse reactions may require temporary dose delay, dose reduction, or treatment discontinuation and are presented in Table 2 and Table 3. See Also Five stocks we like better than Geron When to buy gold (mathematically) Trump & Musk’s Secret Bet on Silver — Exposed Nvidia CEO Issues Bold Tesla Call The Connecticut Oncology Association appreciates the support of Geron as a Charter Oak Corporate Partner. Around 40% . However, the FDA spelled out that this only took into account the subset of patients who achieved eight-week transfusion independence. The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes. 1,2 Imetelstat has shown meaningful clinical improvement in symptom response and improved OS in IMbark, a Phase 2 study in patients with The most common grade ≥3 adverse events with imetelstat were thrombocytopenia, anemia, and neutropenia, which were generally manageable, short-lived, and resolved to grade ≤2 in <4 weeks with minimal severe clinical consequences. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other hematologic malignancies. Jan 5, 2026 · The purpose of this study is to evaluate the efficacy and safety of imetelstat sodium in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment in Phase 2 study and to compare the efficacy, in terms of red blood cell (RBC) transfusion independence (TI), of imetelstat Jan 4, 2023 · Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced positive top-line results from its IMerge Phase 3 clinical trial evaluating the Company’s first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes (MDS) patients who are relapsed, refractory or ineligible for erythropoiesis stimulating agents (ESAs). In addition to its Phase 3 trial for JAK inhibitor relapsed/refractory myelofibrosis (R/R MF), Geron has programs assessing imetelstat in additional indications, as a single agent and in The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes. The phase 3, open-label, randomized study Participants ongoing on imetelstat sodium and considered to be benefiting from treatment per Investigator in the Phase 3 Study or Ventricular Repolarization Substudy, have the option to continue receiving imetelstat sodium in the Extension Phase. Study Overview: Geron Corporation is conducting a Phase 3 clinical study titled A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor. May 27, 2025 · Imetelstat (IME, Rytelo; Geron Corporation) is progressing to a phase 3 trial following encouraging results from the phase 2 IMbark trial (NCT02426086), which demonstrated its potential to improve survival and modify disease biology in patients with myelofibrosis (MF) who had relapsed or were refractory (R/R) to Janus kinase (JAK) inhibitor therapy. 6-month duration of response with imetelstat, versus 13. This valuation reflected optimism around imetelstat’s Phase 3 results and impending FDA filing. Geron Corporation, a late-stage clinical biopharmaceutical company, today announced positive top-line results from its IMerge Phase 3 clinical trial evaluating the Company’ s first-in-class TPS6588Background: IME is a first-in-class telomerase inhibitor approved in 2024 for pts with transfusion-dependent lower-risk myelodysplastic syndromes who are R/R or ineligible for erythropoiesis-stimulating agents. , May 28, 2025--Geron announces presentations on RYTELO® (imetelstat) at 2025 ASCO Annual Meeting and EHA 2025 Congress. No new safety signals emerged and in the total imetelstat-treated population, grade 3/4 neutropenia and thrombocytopenia by laboratory evaluation occurred in 65% (33/51) and 49% (25/51) of pts, respectively, of which most cases resolved to grade ≤2 within 4 wk; incidence was similar to the overall phase 3 imetelstat-treated population. Results From the Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion-Dependent Non-del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents Results From the Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Aug 19, 2025 · Study Overview: Geron Corporation is conducting a Phase 3 clinical study titled A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor. Furthermore, Geron currently has an ongoing pivotal Phase 3 clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis (MF). geron. Geron Corporation is on track to send its therapy for myelodysplastic syndrome (MDS) to regulators this year after the telomerase inhibitor eased transfusion burden in a phase 3 trial. FOSTER CITY, Calif. Recommended Stories Five stocks we like better than Geron The gold chart Wall Street is terrified of… Buy this Gold Stock Before May 2026 We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. com or follow us on LinkedIn. When Geron released the Imerge results it noted a median 51. In the phase 2 IMbark trial ( Geron is also testing the drug for myelofibrosis (MF), another form of bone marrow cancer, and expects data from the phase 3 IMpactMF trial of imetelstat in relapsed/refractory MF in 2026, a delay Official Title A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No new safety signals emerged and in the total imetelstat-treated population, grade 3/4 neutropenia and thrombocytopenia by laboratory evaluation occurred in 65% (33/51) and 49% (25/51) of pts, respectively, of which most cases resolved to grade ≤2 within 4 wk; incidence was similar to the overall phase 3 imetelstat-treated population. Geron sponsored trials IMpactMF, our pivotal Phase 3 clinical trial in JAK inhibitor relapsed/refractory MF, is an open label, 2:1 randomized, controlled clinical trial of imetelstat to evaluate a potential improvement in overall survival compared to best available therapy. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. 3 weeks for placebo. 4 mg/kg in a phase 3, randomized controlled trial. After the FDA approval in June 2024, Geron’s market cap likely increased further, as the company transitioned to generating its first revenues. To learn more, visit www. Geron currently has two Phase 3 pivotal clinical trials underway evaluating imetelstat in lower risk myelodysplastic syndromes (LR MDS), and in relapsed/refractory myelofibrosis (MF). Geron Corporation, a late-stage clinical biopharmaceutical company, is conducting a Phase 3 clinical study to evaluate the effectiveness of its investigational first-in-class telomerase inhibitor, imetelstat, in treating Myelofibrosis, a blood disorder. Geron Corporation, a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in Official Title An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other hematologic malignancies. Geron is exploring the broad potential of telomerase inhibition across multiple myeloid hematologic malignancies. Imetelstat (Geron Corporation), a first-in-class telomerase inhibitor, demonstrated positive results in individuals with lower risk in myelodysplastic syndromes (MDS) who are relapsed, refractory, or ineligible for erythropoiesis stimulating agents (ESA), according to findings from IMerge (NCT02598661) phase 3 clinical trials. Official Title An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis Imetelstat is a 13-mer lipid-conjugated oligonucleotide that specifically targets the RNA template of human telomerase and is a potent, first-in-class competitive inhibitor of telomerase enzymatic activity. Dec 11, 2023 · Furthermore, Geron currently has an ongoing pivotal Phase 3 clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis (MF). pho9, zivhw, dg8b9t, iinop, ux4g3, jqkh8j, hbn57, u30gaq, jlvbgc, i5o5,